Core Insights - Glucotrack, Inc. is preparing to file an Investigational Device Exemption (IDE) for its novel continuous blood glucose monitoring (CBGM) technology, aiming to launch clinical trials in the U.S. in the second half of 2026 [1][2] Corporate Highlights - The company made significant progress in 2025, including the issuance of three new patents by the USPTO, which enhances its competitive position and intellectual property portfolio [2][5] - A long-term multicenter feasibility study for the CBGM product was initiated in Australia [4] - A private placement raised approximately $4.0 million, which will be used for working capital and general corporate purposes [5] - The company appointed Dr. Usman Latif to its clinical advisory team, bringing expertise in pain management and diabetic neuropathy [5] Product and Clinical Development - The first phase of the clinical study provided insights into product improvements and eligibility criteria, leading to expedited discussions with the FDA regarding the planned U.S. clinical trial program [6] - The company presented at the 2025 Diabetes Technology Meeting, emphasizing the integration of continuous glucose monitoring with existing implantable technologies [6] Financial Results - Research and development expenses for 2025 were $9.8 million, a slight increase from $9.5 million in 2024, primarily due to heightened product design and development activities [8] - General and administrative expenses rose to $6.3 million in 2025 from $5.1 million in 2024, mainly due to increased professional fees and personnel costs [9] - The net loss for 2025 was $19.4 million, a decrease from $22.6 million in 2024, attributed to non-cash losses recognized in the prior year [10] - Cash and cash equivalents increased to $7.4 million as of December 31, 2025, compared to $5.6 million in 2024, supported by financing activities [11] Anticipated Milestones - The company plans to submit its IDE to the FDA in the second quarter of 2026 to initiate a human clinical feasibility study of the CBGM product [13] - Additional clinical data will be presented at industry conferences to demonstrate the safety and accuracy of the CBGM product [13] - The company aims to expand its advisory boards with experts in endocrinology and cardiology to enhance its diabetes management solutions [13]

Core Insights - Glucotrack, Inc. is preparing to submit an Investigational Device Exemption (IDE) to the U.S. FDA for its continuous blood glucose monitoring (CBGM) technology, aiming for submission in Q2 2026 [1] Group 1: Operational Milestones - The company completed its first-in-human study in Brazil, which involved ten participants with diabetes, demonstrating successful insertion and removal of the device [3] - The study achieved a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs, with a 99% data capture rate and no serious adverse events [4] - A follow-up feasibility clinical trial was initiated in Australia, providing valuable insights for future studies [5] Group 2: Market and Commercial Strategy - Extensive U.S. market research indicates a significant unmet need for a fully implantable CBGM solution, highlighting the potential for a scalable impact on millions of diabetes patients [2] - The company has identified a clear U.S. reimbursement pathway and established a dual-source manufacturing strategy with qualified partners [2] - A seasoned management team with experience from industry leaders has been assembled to support the company's growth [2] Group 3: Clinical Trial Readiness - Key activities for U.S. clinical trial readiness have been completed, including securing a trial site and engaging a Clinical Research Organization experienced in diabetes Medtech [6] - Discussions with the FDA regarding the planned U.S. clinical trial program are ongoing, with expectations to initiate the study in the second half of 2026, pending FDA approval [7] Group 4: Intellectual Property - The company was awarded three critical patents for its CBGM platform, enhancing its intellectual property portfolio and supporting its go-to-market strategy [8][9]

Core Insights - Glucotrack, Inc. is set to present its continuous blood glucose monitor (CBGM) technology at the LSI USA '26 Summit, highlighting its innovative approach to diabetes management [1][2]. Company Overview - Glucotrack, Inc. focuses on the design, development, and commercialization of novel technologies for diabetes management, specifically a long-term implantable continuous blood glucose monitoring system [4]. - The CBGM system is designed to measure blood glucose levels continuously, featuring a sensor longevity of up to three years, no on-body wearable component, and minimal calibration requirements [5]. Presentation Details - Dr. Paul V. Goode will present on March 17, 2026, at 8:15 a.m. PT, discussing the positive results from the first-in-human study, regulatory strategy, and commercialization plans for a U.S. clinical trial [2][3]. - The presentation aims to address substantial unmet needs in diabetes management and promote a user-friendly experience for patients [3].

Core Insights - Glucotrack, Inc. is set to present its continuous blood glucose monitor (CBGM) technology at the LSI USA '26 Summit, highlighting its innovative approach to diabetes management [1][2][3] Company Overview - Glucotrack, Inc. focuses on the design, development, and commercialization of novel technologies for diabetes management, specifically a long-term implantable continuous blood glucose monitoring system [4] - The CBGM is designed to measure blood glucose levels continuously with a sensor longevity of up to three years, featuring no on-body wearable component and minimal calibration requirements [5] Presentation Details - Dr. Paul V. Goode will present on March 17, 2026, at 8:15 a.m. PT, discussing the positive results from the first-in-human study, regulatory strategy, and commercialization plans for a U.S. clinical trial [2][3] - The presentation aims to address substantial unmet needs in diabetes management and promote a user-friendly experience for patients [3]

Core Viewpoint - Glucotrack, Inc. has received three patents for its continuous blood glucose monitoring (CBGM) platform, enhancing its competitive position and intellectual property protection as it moves towards commercialization of its fully implantable system [1][4]. Patent Details - The patents cover essential technologies in Glucotrack's CBGM system, including proprietary sensor chemistry, intravascular lead design, and low-power electronics [2]. - The patents issued are US 12,453,494, US 12,458,257, and US 12,458,258, which focus on improving glucose measurement methods and sensor design [9]. Product Features - Glucotrack's CBGM is designed for long-term implantation, with a sensor longevity of up to three years and no wearable components, providing a more convenient glucose monitoring solution [4][6]. - The system measures glucose directly from blood, aiming to deliver real-time readings without the lag associated with traditional interstitial fluid measurements [4]. Strategic Importance - Securing these patents is a significant milestone for Glucotrack, as it establishes competitive barriers and strengthens the company's position in the diabetes management market [4].

Core Viewpoint - Glucotrack, Inc. has entered into a securities purchase agreement with an institutional investor to raise approximately $4.0 million through the sale of common stock and warrants, aimed at supporting its operations and development of diabetes-related technologies [1][2]. Group 1: Securities Offering - The company will sell 1,033,591 shares of common stock and warrants to purchase up to 2,067,182 shares at an effective combined price of $3.87 per share, resulting in gross proceeds of about $4.0 million before expenses [1]. - The closing of the offering is anticipated to occur on or about December 31, 2025, pending customary closing conditions [2]. - The warrants will have an exercise price of $3.87 per share, will require shareholder approval before being exercisable, and will expire five years from the initial exercise date [1]. Group 2: Use of Proceeds - The net proceeds from the offering are expected to be utilized for working capital and general corporate purposes [2]. Group 3: Company Overview - Glucotrack, Inc. focuses on the design, development, and commercialization of innovative technologies for diabetes management [5]. - The company is developing a long-term implantable continuous blood glucose monitoring system, which features a sensor longevity of three years and minimal calibration requirements [6].

Core Insights - Glucotrack, Inc. has appointed Dr. Usman Latif to its clinical advisory team to enhance its strategy for integrated glucose monitoring applications, particularly focusing on epidural glucose monitoring alongside its continuous blood glucose monitor (CBGM) [1][5]. Company Overview - Glucotrack, Inc. specializes in the design, development, and commercialization of innovative technologies for diabetes management, including a long-term implantable continuous blood glucose monitoring system [8][9]. Key Developments - The company has successfully completed a long-term preclinical study demonstrating the feasibility and safety of glucose monitoring in the epidural space, which builds on its existing glucose sensing capabilities [5]. - Dr. Latif's expertise in pain management and neuromodulation is expected to significantly contribute to the development of integrated disease and device management solutions for patients suffering from Painful Diabetic Neuropathy (PDN) [2][4]. Market Context - PDN affects approximately 20% of the over 38 million Americans with diabetes, translating to more than 7 million individuals, highlighting a significant market opportunity for integrated glucose monitoring solutions [4]. - Spinal Cord Stimulation (SCS) technology has been recognized as an effective treatment option for providing long-term pain relief to PDN patients, which aligns with Glucotrack's vision of integrating glucose monitoring into existing pain management therapies [4].

Core Viewpoint - Glucotrack, Inc. is making significant advancements in the development of its fully implantable continuous blood glucose monitor (CBGM) system, with plans to initiate clinical studies in Australia and submit an Investigational Device Exemption (IDE) to the FDA by the end of 2025, while also strengthening its corporate structure and expanding its advisory boards [1][2][11]. Corporate Highlights - The company is on track to implant the first patients in a long-term, multicenter feasibility study of the CBGM system in Australia in Q3 2025 [1]. - An IDE submission to the FDA for the novel CBGM technology is anticipated in Q4 2025 [1]. - The Board of Directors has been strengthened with the appointment of Dr. David S. Hirsh as Medical Director - Cardiology and Dr. Victoria E. Carr-Brendel to the Board [2][5]. - A Patient Advisory Board has been established to incorporate patient perspectives into the development of the CBGM technology [2][5]. Financial Overview - Cash and cash equivalents as of June 30, 2025, were $9.6 million, an increase from $5.6 million as of December 31, 2024, primarily due to $10.7 million in net proceeds from public equity financings [12]. - Research and development expenses for the six months ended June 30, 2025, were $5.0 million, down from $5.7 million in the prior-year period [8]. - Marketing, general, and administrative expenses increased to $3.3 million for the six months ended June 30, 2025, compared to $1.7 million in the prior-year period [9]. - The net loss for the six months ended June 30, 2025, was $11.6 million, compared to a net loss of $7.4 million for the same period in the previous year [10]. Clinical Development - Positive results were reported from a first-in-human study for the CBGM, achieving a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs, with a 99% data capture rate [11]. - The company received ethical approval in Australia to initiate a long-term clinical study of the CBGM in participants with type 1 and type 2 diabetes [11]. - Glucotrack is participating in the FORGETDIABETES initiative, which aims to develop an artificial pancreas for type 1 diabetes, utilizing the CBGM technology for real-time glucose data [11].

Company Overview - Glucotrack, Inc. is a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes [5] - The company is developing a long-term implantable continuous blood glucose monitoring system [5][6] Product Details - Glucotrack's Continuous Blood Glucose Monitor (CBGM) is designed to measure blood glucose levels directly from the blood, without the need for on-body wearables, and has a sensor longevity of up to three years [3][6] - The CBGM aims to minimize daily disruptions for diabetes patients by addressing limitations of traditional continuous glucose monitors (CGM), such as frequent sensor changes and challenges associated with on-body wearables [3] Upcoming Events - Glucotrack will participate in the 2025 Association of Diabetes Care and Education Specialists (ADCES) Annual Meeting from August 8-11, 2025, in Phoenix, AZ [1] - The company will showcase its CBGM at Booth 1724 and present a poster on physician perspectives regarding continuous blood glucose monitoring technology [2][3]

Core Insights - Glucotrack's Continuous Blood Glucose Monitor (CBGM) technology has demonstrated safety and accuracy with a Mean Absolute Relative Difference (MARD) of 7.7% in a first-in-human clinical study [1][2][5] Study Results - The clinical study met all primary and secondary endpoints, achieving a 99% data capture rate and no serious adverse events related to the procedure or device [2][4] - Analysis showed that 92% of CBGM measurement values were in the green zone according to the Diabetes Technology Society Error Grid, indicating high clinical accuracy [3] Technology Overview - The CBGM is a fully implantable system that measures glucose directly from blood, eliminating lag time associated with traditional interstitial fluid monitors [6] - Designed for a three-year sensor life, the system requires minimal calibration and has no on-body wearable component, offering a less intrusive solution for diabetes management [6][11] Future Plans - Glucotrack plans to initiate a long-term early feasibility study in Q3 2025 to further evaluate the safety and performance of the CBGM technology [5]